CA2384948C - Therapies for chronic renal failure using one or more integrin antagonists - Google Patents

Therapies for chronic renal failure using one or more integrin antagonists Download PDF

Info

Publication number
CA2384948C
CA2384948C CA2384948A CA2384948A CA2384948C CA 2384948 C CA2384948 C CA 2384948C CA 2384948 A CA2384948 A CA 2384948A CA 2384948 A CA2384948 A CA 2384948A CA 2384948 C CA2384948 C CA 2384948C
Authority
CA
Canada
Prior art keywords
binding fragment
antigen binding
antibody
intact antibody
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2384948A
Other languages
English (en)
French (fr)
Other versions
CA2384948A1 (en
Inventor
Andrew Allen
Charles Pusey
Roy Lobb
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imperial College London
Biogen MA Inc
Original Assignee
Imperial College London
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imperial College London, Biogen Idec MA Inc filed Critical Imperial College London
Publication of CA2384948A1 publication Critical patent/CA2384948A1/en
Application granted granted Critical
Publication of CA2384948C publication Critical patent/CA2384948C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2384948A 1999-09-14 2000-09-14 Therapies for chronic renal failure using one or more integrin antagonists Expired - Fee Related CA2384948C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15382699P 1999-09-14 1999-09-14
US60/153,826 1999-09-14
PCT/US2000/025140 WO2001019396A1 (en) 1999-09-14 2000-09-14 Therapies for chronic renal failure using one or more integrin antagonists

Publications (2)

Publication Number Publication Date
CA2384948A1 CA2384948A1 (en) 2001-03-22
CA2384948C true CA2384948C (en) 2013-07-16

Family

ID=22548902

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2384948A Expired - Fee Related CA2384948C (en) 1999-09-14 2000-09-14 Therapies for chronic renal failure using one or more integrin antagonists

Country Status (13)

Country Link
US (3) US20030007969A1 (cg-RX-API-DMAC7.html)
EP (1) EP1214091B1 (cg-RX-API-DMAC7.html)
JP (3) JP4975922B2 (cg-RX-API-DMAC7.html)
AT (1) ATE325623T1 (cg-RX-API-DMAC7.html)
AU (1) AU783266B2 (cg-RX-API-DMAC7.html)
CA (1) CA2384948C (cg-RX-API-DMAC7.html)
CY (1) CY1105117T1 (cg-RX-API-DMAC7.html)
DE (1) DE60027907T2 (cg-RX-API-DMAC7.html)
DK (1) DK1214091T3 (cg-RX-API-DMAC7.html)
ES (1) ES2263485T3 (cg-RX-API-DMAC7.html)
NZ (1) NZ517781A (cg-RX-API-DMAC7.html)
PT (1) PT1214091E (cg-RX-API-DMAC7.html)
WO (1) WO2001019396A1 (cg-RX-API-DMAC7.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1506359A (zh) 2002-12-05 2004-06-23 �й�ҽѧ��ѧԺҩ���о��� 新的香豆素酰胺衍生物及其制法和其药物组合物与用途
US7767219B2 (en) 2003-01-31 2010-08-03 Boston Scientific Scimed, Inc. Localized drug delivery using drug-loaded nanocapsules
US20070048383A1 (en) * 2005-08-25 2007-03-01 Helmus Michael N Self-assembled endovascular structures
DE102009000854A1 (de) * 2009-02-13 2010-08-19 Ernst-Moritz-Arndt-Universität Greifswald Osteopontin-Rezeptor-Liganden zur Behandlung des chronischen Nierenversagens
EP4720125A1 (en) 2023-05-30 2026-04-08 Paragon Therapeutics, Inc. Alpha4beta7 integrin antibody compositions and methods of use
EP4762093A1 (en) 2023-08-14 2026-06-24 Paragon Therapeutics, Inc. Alpha 4 beta 7 integrin binding proteins and methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4111657A (en) * 1977-01-21 1978-09-05 American Monitor Corporation Creatinine assay and reagent system
US5272263A (en) * 1989-04-28 1993-12-21 Biogen, Inc. DNA sequences encoding vascular cell adhesion molecules (VCAMS)
US6307025B1 (en) * 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5217870A (en) * 1989-04-28 1993-06-08 Biogen, Inc. Monoclonal antibodies against CDX
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) * 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
USRE40811E1 (en) * 1992-11-13 2009-06-30 Board Of Regents Of The University Of Washington Peripheralization of hematopoietic stem cells
SG44845A1 (en) * 1993-01-12 1997-12-19 Biogen Inc Recombitant anti-vla4 antibody molecules
WO1994017828A2 (en) * 1993-02-09 1994-08-18 Biogen, Inc. Treatment for insulin dependent diabetes
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6498142B1 (en) * 1996-05-06 2002-12-24 Curis, Inc. Morphogen treatment for chronic renal failure
JP2000516596A (ja) * 1996-07-25 2000-12-12 バイオジェン，インコーポレイテッド 細胞接着インヒビター
ES2285841T3 (es) * 1998-05-22 2007-11-16 Boys Town National Research Hospital Uso de inhibidores del receptor de integrina alfa1beta1 e inhibidores de tgf-beta1 en el tratamiento de la enfermedad renal.
US7618630B2 (en) * 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
ES2319831T3 (es) * 1998-09-14 2009-05-12 Board Of Regents, The University Of Texas System Metodos de tratamiento de mieloma multiple y resorcion osea inducida por mieloma usando antagonistas de la union receptor/integrina.
US6245885B1 (en) * 1998-10-05 2001-06-12 Mcgill University Bax-mediated apoptosis modulating reagents and methods
AU783110B2 (en) * 1999-12-16 2005-09-22 Biogen Ma Inc. Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists

Also Published As

Publication number Publication date
DE60027907D1 (de) 2006-06-14
DE60027907T2 (de) 2007-01-04
US20110305686A1 (en) 2011-12-15
ATE325623T1 (de) 2006-06-15
JP2013116916A (ja) 2013-06-13
EP1214091A1 (en) 2002-06-19
JP2011116791A (ja) 2011-06-16
ES2263485T3 (es) 2006-12-16
CA2384948A1 (en) 2001-03-22
AU783266B2 (en) 2005-10-06
NZ517781A (en) 2004-01-30
PT1214091E (pt) 2006-09-29
US20140234299A1 (en) 2014-08-21
EP1214091B1 (en) 2006-05-10
JP2003509380A (ja) 2003-03-11
WO2001019396A1 (en) 2001-03-22
US20030007969A1 (en) 2003-01-09
JP4975922B2 (ja) 2012-07-11
AU7379200A (en) 2001-04-17
CY1105117T1 (el) 2010-03-03
DK1214091T3 (da) 2006-08-28
JP5463316B2 (ja) 2014-04-09

Similar Documents

Publication Publication Date Title
US20150056205A1 (en) Steroid sparing agents and methods of using same
CA2370814C (en) Method for the treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
ES2319831T3 (es) Metodos de tratamiento de mieloma multiple y resorcion osea inducida por mieloma usando antagonistas de la union receptor/integrina.
NZ519447A (en) Methods of treating central nervous system ischemic or hemorrhagic injury using anti alpha4 integrin antagonists
US20140234299A1 (en) Therapies for chronic renal failure using one or more integrin antagonists
EP1700606A1 (en) Therapies for chronic renal failure using one or more integrin antagonists
HK1094948A (en) Therapies for chronic renal failure using one or more integrin antagonists
AU2011213878B2 (en) Steroid sparing agents and methods of using same
HK1092714A (en) Method for treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
EP1666063A2 (en) Method for treatment of fibrosis using an antagonist of the integrin alpha-4 subunit
HK1038313B (en) Methods of treating multiple myeloma and myeloma-induced bone resorption using antagonists of integrin / receptor binding

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160914